Bavarian Nordic has signed a joint procurement agreement with HERA, the European Commission’s Health Emergency Preparedness and Response Authority, for the supply of up to 2 million doses of the Imvanex (Jynneos) monkeypox vaccine during 2023 and 2024.
Bavarian Nordic has entered into an agreement with Grand River Aseptic Manufacturing (GRAM), a US based contract manufacturer, for fill and finish of the Jynneos smallpox/monkeypox vaccine in the country.
Bavarian Nordic A/S has received approvals from the US and EU regulatory authorities to manufacture its Jynneos/Imvanex smallpox and monkeypox vaccine at its fill and finish facility in Denmark.
The Coalition for Epidemic Preparedness Innovations (CEPI) will provide funding of up to $375,000 to the UK Medicines and Healthcare products Regulatory Agency (MHRA) and the UK Health Security Agency (UKHSA) to support the development of laboratory tools...
The European Commission has extended the marketing authorization for Bavarian Nordic’s smallpox vaccine, Imvanex, to include protection from monkeypox and disease caused by vaccinia virus.
Interest in vaccines against monkeypox is growing as the outbreak spreads around the world. The arsenal includes existing smallpox vaccines and potential new monkeypox specific mRNA vaccines.
Danish vaccine company Bavarian Nordic has entered several new supply contracts with countries for its smallpox vaccine, with deliveries set to start immediately.
